Major Institutional Investor Files Intent to Sell Over $1.7M in Protara Therapeutics Stock
Summary
667, L.P., an institutional investor affiliated with Baker Brothers Life Sciences, L.P., filed a Form 144 indicating intent to sell 24,802 shares of Protara Therapeutics common stock, part of a larger combined proposed sale of over $1.7 million by affiliated entities.
Key Events
-
Intent to Sell Filed
667, L.P. filed a Form 144 to sell 24,802 shares of Protara Therapeutics common stock, with an approximate market value of $132,691.00.
-
Significant Combined Disposition
This proposed sale is part of a larger disposition, with affiliated entity Baker Brothers Life Sciences, L.P. also filing separately to sell 300,176 shares, totaling approximately $1.71 million in combined proposed sales by the affiliated entities.
-
Ongoing Selling Pattern
This filing continues a pattern of sales by 667, L.P. and its affiliates, with 9 similar filings in the last 90 days, indicating a sustained reduction in their holdings.
Analysis
This Form 144 signals a continued disposition of shares by a significant institutional investor, 667, L.P., and its affiliate Baker Brothers Life Sciences, L.P. The combined proposed sale of over $1.7 million represents a notable reduction in their stake, following a pattern of sales over the past 90 days. While the company recently highlighted positive clinical developments and is seeking to increase authorized shares, this selling activity by a major investor could be interpreted as a lack of conviction or a strategic rebalancing, potentially adding selling pressure to the stock.
At the time of this filing, TARA was trading at $5.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $284.5M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.